A Phase I Clinical Study to evaluate PMI-06 in Patients with Non-Small Cell Lung Cancer
Latest Information Update: 29 Sep 2021
At a glance
- Drugs PMI 06 (Primary)
- Indications Cancer; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Precision Molecular
- 29 Sep 2021 New trial record
- 28 Sep 2021 According to a Precision Molecular media release, this trial is expected to start in this year.